Setmelanotide for the Treatment of Acquired Hypothalamic Obesity
New England Journal of Medicine · 09.07.2026 · 395 (2) · 138-150
DOI: 10.1056/nejmoa2512275 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.07.2026. Verfasst von Jennifer L Miller und 33 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, Gainesville. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Hypothalamic Diseases, Obesity, Receptor, Melanocortin, Type 4. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Rhythm Pharmaceuticals, Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, Gainesville.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
- Rady Children's Hospital, San Diego.
- Department of Pediatrics, Division of Endocrinology, University of California, San Diego, San Diego.
- Division of Endocrinology, Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto.
ORCID-Profile: Ashley H Shoemaker, Martin Wabitsch, Vanita R Aroda, Keisuke Nagasaki, Tomohiro Tanaka, Tsuyoshi Isojima, Christian L Roth
Förderung
- Rhythm Pharmaceuticals, Inc.
Zitieren
APA
Miller, J. L., van Santen, H. M., Phillips, S. A., Hamilton, J., Aberle, J., Sathyapalan, T., Mohamed, Z., McCormack, S. E., Shoemaker, A. H., Kelsey, M. M., Ghalib, L., Stalla, G., Thaker, V. V., Habiby, R., Ode, K. L., Wabitsch, M., Dattani, M., Abuzzahab, M. J., Abdullatif, H., …, & TRANSCEND Trial Group (2026). Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. New England Journal of Medicine, 395(2), 138-150. https://doi.org/10.1056/nejmoa2512275
Vancouver
Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. New England Journal of Medicine. 2026;395(2):138-150. doi:10.1056/nejmoa2512275
BibTeX
@article{Miller2026,
author = {Miller, Jennifer L and van Santen, Hanneke M and Phillips, Susan A and Hamilton, Jill and Aberle, Jens and Sathyapalan, Thozhukat and Mohamed, Zainaba and McCormack, Shana E and Shoemaker, Ashley H and Kelsey, Megan M and Ghalib, Luma and Stalla, Guenter and Thaker, Vidhu V and Habiby, Reema and Ode, Katie Larson and Wabitsch, Martin and Dattani, Mehul and Abuzzahab, M Jennifer and Abdullatif, Hussein and Morgan, Ryan and Stefater-Richards, Margaret and Aroda, Vanita R and Friedrich, Carsten and Han, Joan C and Ono, Hiraku and Nagasaki, Keisuke and Tanaka, Tomohiro and Isojima, Tsuyoshi and Arima, Hiroshi and Scimia, Cecilia and Yuan, Guojun and Müller, Hermann L and Roth, Christian L and TRANSCEND Trial Group, TRANSCEND Trial Group},
title = {Setmelanotide for the Treatment of Acquired Hypothalamic Obesity},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {2},
pages = {138--150},
doi = {10.1056/nejmoa2512275}
}
EUVIMED